Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AERI
  • CUSIP: N/A
  • Web: www.aeriepharma.com
Capitalization:
  • Market Cap: $1.99359 billion
  • Outstanding Shares: 33,634,000
Average Prices:
  • 50 Day Moving Avg: $53.86
  • 200 Day Moving Avg: $46.51
  • 52 Week Range: $16.61 - $59.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.89
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.50 per share
  • Price / Book: 23.12
Profitability:
  • EBIDTA: ($99,150,000.00)
  • Return on Equity: -136.01%
  • Return on Assets: -47.53%
Debt:
  • Debt-to-Equity Ratio: 1.47%
  • Current Ratio: 15.50%
  • Quick Ratio: 15.50%
Misc:
  • Average Volume: 595,567 shs.
  • Beta: 1.16
  • Short Ratio: 4.48
 
Frequently Asked Questions for Aerie Pharmaceuticals (NASDAQ:AERI)

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.02. View Aerie Pharmaceuticals' Earnings History.

When will Aerie Pharmaceuticals make its next earnings announcement?

Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Aerie Pharmaceuticals.

Where is Aerie Pharmaceuticals' stock going? Where will Aerie Pharmaceuticals' stock price be in 2017?

12 brokerages have issued 1-year price objectives for Aerie Pharmaceuticals' shares. Their predictions range from $48.00 to $100.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $65.67 in the next year. View Analyst Ratings for Aerie Pharmaceuticals.

What are analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. Aerie had earlier withdrawn its NDA that was filed in September as a third party manufacturing facility in Tampa, FL was not ready for pre-approval inspection by the FDA. A potential approval and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. The recent data on Roclatan is also positive. Moreover, Aerie’s shares have outperformed the industry in the last 12 monts. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa." (7/11/2017)
  • 2. HC Wainwright analysts commented, "Blueprint reported a Q1 net loss of $28MM and ended the quarter with $452MM." (5/3/2017)
  • 3. Aegis analysts commented, "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event. Higher patients dropout rate seen in Rhopressa arm relative to Timolol arm is not concerning to us. 30% of the patients in the Rhopressa arm of the trial discontinued treatment by month 6 compared to 12% of the patient population in the Timolol arm. The most common reason for discontinuation seen in the Rhopressa arm was related to adverse events, at about 19.4%. 2.2% (8) of the subjects in the Timolol arm dropped out due to adverse events. As a point of reference, given that 47% of patients (118 out of 251 patients) on Rhopressa QD completed the treatment by month 12 in Rocket 2, we estimate a maximum drop-off rate of Rhopressa at 53%. Further, according to results published in Persistency: A New Take on Patient Care" by Schwartz in Review of Ophthalmology 11.4 (2004): 108, the discontinuation rates of 66%/50%/46% for Latanoprost/Travoprost/Bimatoprost were seen at month 3 and 6, with rates increasing to 67%/81%/81%, respectively, at month 12." (4/13/2017)
  • 4. Needham & Company LLC analysts commented, " AERI reported 4Q16 financials and updated ongoing Rhopressa and Roclatan development activities. The Rhopressa NDA was refiled in late Feb following an issue at the third party manufacturer. AERI expects a potential PDUFA in 1Q18 after a standard FDA review and is in the process of building a commercial org in anticipation of a 1H18 product launch. Key data from both Rhopressa and Roclatan are expected in 2Q17: top-line safety data from the ph 3 ROCKET-4 trial and top-line efficacy data from the ph 3 MERCURY-2 trial. AERI expects to file an NDA for Roclatan in late 2017/early 2018. We maintain our Buy rating and slightly adjust our $PT to $58 (from $52) to reflect a model and valuation update." (3/8/2017)
  • 5. Brean Capital analysts commented, "At yesterday’s investor day, Aerie painted a clearer portrait of the current standard of care and competitive glaucoma treatment environment. Management also provided further insight into the recent Mercury 1 data for Roclatan, a closer look at how to measure the effectiveness of glaucoma treatment with added perspective from a former physician, as well as revisited what the company’s future value adding drivers will be and articulated the international strategy. We took the opportunity to dive deeper into our model, taking into account potential future European launches and Japanese clinical trials." (10/6/2016)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:

  • Vicente Anido Jr., Ph.D., Chairman of the Board, Chief Executive Officer
  • Thomas A. Mitro, President, Chief Operating Officer
  • Casey C. Kopczynski Ph.D., Co-Founder, Chief Scientific Officer
  • Richard J. Rubino CPA, Chief Financial Officer, Secretary
  • Gerald D. Cagle Ph.D., Independent Director
  • Richard J. Croarkin, Independent Director
  • Michael M. Du Toit, Independent Director
  • Geoffrey M. Duyk M.D. Ph.D., Independent Director
  • Murray A. Goldberg, Independent Director

Who owns Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Handelsbanken Fonder AB (0.39%), Handelsinvest Investeringsforvaltning (0.13%), Legato Capital Management LLC (0.12%), Harvey Capital Management Inc. (0.08%), Fox Run Management L.L.C. (0.04%) and Aperio Group LLC (0.01%). Company insiders that own Aerie Pharmaceuticals stock include Foresite Capital Fund Ii, LP, Geoffrey M Duyk and Gerald D Cagle. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Who sold Aerie Pharmaceuticals stock? Who is selling Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Harvey Capital Management Inc. and Creative Planning. Company insiders that have sold Aerie Pharmaceuticals stock in the last year include Foresite Capital Fund Ii, LP and Geoffrey M Duyk. View Insider Buying and Selling for Aerie Pharmaceuticals.

Who bought Aerie Pharmaceuticals stock? Who is buying Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Handelsinvest Investeringsforvaltning, Legato Capital Management LLC, Fox Run Management L.L.C. and Aperio Group LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP and Gerald D Cagle. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy Aerie Pharmaceuticals stock?

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $57.80.


MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
Community Ranking:  4.2 out of 5 (   )
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $65.67 (13.61% upside)

Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017Cantor FitzgeraldReiterated RatingOverweight -> Overweight$56.00 -> $62.00HighView Rating Details
7/4/2017Stifel NicolausBoost Price TargetBuy$55.00 -> $65.00MediumView Rating Details
7/3/2017Canaccord GenuityReiterated RatingBuy$65.00MediumView Rating Details
5/26/2017Cowen and CompanySet Price TargetBuy$100.00N/AView Rating Details
5/25/2017AegisBoost Price TargetBuy$63.00 -> $70.00HighView Rating Details
5/25/2017HC WainwrightReiterated RatingBuy$69.00HighView Rating Details
5/25/2017Needham & Company LLCBoost Price TargetBuy -> Buy$58.00 -> $65.00HighView Rating Details
3/31/2017JMP SecuritiesReiterated RatingOutperform$57.00LowView Rating Details
3/9/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Market Perform$48.00LowView Rating Details
3/8/2017Royal Bank Of CanadaBoost Price TargetOutperform$54.00 -> $55.00MediumView Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 -> $63.00N/AView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Earnings History by Quarter for Aerie Pharmaceuticals (NASDAQ AERI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017($0.62)N/AView Earnings Details
5/2/2017Q1 2017($0.74)($0.76)ViewListenView Earnings Details
3/7/2017Q4 2016($0.67)($0.87)ViewListenView Earnings Details
11/2/2016Q316($0.70)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.69)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.73)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.51)($0.69)ViewN/AView Earnings Details
11/11/2014Q3 2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.37)($0.49)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)
Current Year EPS Consensus Estimate: $-3.21 EPS
Next Year EPS Consensus Estimate: $-2.64 EPS

Dividends

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Ownership Percentage: 9.36%
Institutional Ownership Percentage: 91.90%
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Foresite Capital Fund Ii, L.P.Major ShareholderSell20,000$55.95$1,119,000.00View SEC Filing  
4/19/2017Gerald D CagleDirectorBuy2,000$41.70$83,400.00View SEC Filing  
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.33View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aerie Pharmaceuticals (NASDAQ:AERI)
Latest Headlines for Aerie Pharmaceuticals (NASDAQ:AERI)
Source:
DateHeadline
nasdaq.com logoCommit To Purchase Aerie Pharmaceuticals At $40, Earn 13% Using Options - Nasdaq
www.nasdaq.com - July 21 at 4:51 PM
americanbankingnews.com logoInsmed (INSM) versus Aerie Pharmaceuticals (AERI) Head to Head Survey
www.americanbankingnews.com - July 21 at 2:26 PM
reuters.com logoBRIEF-Aerie Pharmaceuticals reports positive Roclatan phase 3 12-month topline safety results
www.reuters.com - July 21 at 2:59 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Price Target Raised to $62.00 at Cantor Fitzgerald
www.americanbankingnews.com - July 20 at 8:23 PM
seekingalpha.com logoAerie Pharma's eye drop Roclatan safe in 12-month study - Seeking Alpha
seekingalpha.com - July 19 at 10:08 PM
reuters.com logoBRIEF-Brian Grossman reports 6.3 pct passive stake in Aerie Pharmaceuticals Inc as of July 5 - SEC filing
www.reuters.com - July 18 at 4:13 PM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 11 at 10:14 PM
reuters.com logoInotek to explore strategic options after eye drug fails trial - Reuters
www.reuters.com - July 8 at 3:15 PM
reuters.com logoInotek to explore strategic options after eye drug fails trial
www.reuters.com - July 8 at 8:11 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - July 3 at 9:02 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - June 30 at 12:44 PM
americanbankingnews.com logo Brokerages Expect Aerie Pharmaceuticals, Inc. (AERI) Will Announce Earnings of -$0.84 Per Share
www.americanbankingnews.com - June 28 at 8:16 PM
americanbankingnews.com logoBidaskClub Lowers Aerie Pharmaceuticals, Inc. (AERI) to Strong Sell
www.americanbankingnews.com - June 17 at 7:52 PM
nasdaq.com logoCan The Uptrend Continue for Aerie Pharmaceuticals (AERI)? - Nasdaq
www.nasdaq.com - June 7 at 3:25 PM
americanbankingnews.com logoAerie Pharmaceuticals Inc (AERI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 5 at 11:11 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Aerie Pharmaceuticals Inc (AERI) Will Post Earnings of -$0.84 Per Share
www.americanbankingnews.com - June 2 at 6:42 PM
americanbankingnews.com logoAerie Pharmaceuticals Inc (AERI) Major Shareholder Foresite Capital Fund Ii, L.P. Sells 20,000 Shares
www.americanbankingnews.com - May 31 at 10:28 PM
seekingalpha.com logoI've Joined Aerie Pharmaceuticals In Selling Its Stock - Seeking Alpha
seekingalpha.com - May 31 at 3:23 PM
americanbankingnews.com logoAerie Pharmaceuticals' (AERI) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - May 27 at 12:08 PM
americanbankingnews.com logoAerie Pharmaceuticals Inc (AERI) Given a $100.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - May 27 at 8:24 AM
businesswire.com logoAerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering - Business Wire (press release)
www.businesswire.com - May 26 at 8:38 PM
finance.yahoo.com logoAerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering
finance.yahoo.com - May 26 at 3:32 PM
finance.yahoo.com logoBioCryst and Aerie Pharmaceuticals' Shares Swell on Positive Study Results
finance.yahoo.com - May 26 at 3:32 PM
finance.yahoo.com logoPharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data
finance.yahoo.com - May 26 at 3:32 PM
finance.yahoo.com logoBiotech Movers: Immunomedics, Aerie, Exelixis
finance.yahoo.com - May 26 at 3:32 PM
reuters.com logoBRIEF-Aerie Pharma to offer common shares in public offering
www.reuters.com - May 26 at 1:55 AM
americanbankingnews.com logoAegis Reaffirms "Buy" Rating for Aerie Pharmaceuticals Inc (AERI)
www.americanbankingnews.com - May 26 at 12:58 AM
americanbankingnews.com logoAerie Pharmaceuticals Inc (AERI) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - May 26 at 12:23 AM
reuters.com logoBRIEF-Aerie Pharmaceuticals enters into controlled equity offering sales agreement with Cantor Fitzgerald - Reuters
www.reuters.com - May 25 at 8:47 PM
marketwatch.com logoAerie Pharma stock surges 32% on positive late-stage trial results for glaucoma eye drops - MarketWatch
www.marketwatch.com - May 25 at 8:47 PM
fool.com logoWhy Aerie Pharmaceuticals Inc. Is Skyrocketing Today - Motley Fool
www.fool.com - May 25 at 8:47 PM
americanbankingnews.com logoAerie Pharmaceuticals Inc (AERI) Given a $69.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 25 at 8:36 PM
americanbankingnews.com logoAerie Pharmaceuticals Inc (AERI) Given a $56.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 25 at 4:56 PM
reuters.com logoBRIEF-Aerie Pharma's Roclatan succeeds in second late-stage study
www.reuters.com - May 25 at 3:44 PM
seekingalpha.com logoAerie Pharmaceuticals (AERI) Updates On Roclatan Mercury Phase 3 Topline Efficacy Results - Slideshow
seekingalpha.com - May 25 at 3:44 PM
feeds.benzinga.com logoHas Aerie Pharma Put The 'Binary Boogeyman' To Bed With Roclatan Phase 3 Data?
feeds.benzinga.com - May 25 at 3:23 PM
fool.com logoWhy Aerie Pharmaceuticals Inc. Is Skyrocketing Today
www.fool.com - May 25 at 1:26 PM
americanbankingnews.com logoNeedham & Company LLC Boosts Aerie Pharmaceuticals Inc (AERI) Price Target to $65.00
www.americanbankingnews.com - May 25 at 11:28 AM
businesswire.com logoAerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase ... - Business Wire (press release)
www.businesswire.com - May 25 at 1:24 AM
rttnews.com logoAerie Pharmaceuticals Inc. (AERI) Is Surging On Phase 3 Study Results
www.rttnews.com - May 24 at 8:23 PM
finance.yahoo.com logoAerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
finance.yahoo.com - May 24 at 8:23 PM
finance.yahoo.com logoAerie Pharma stock surges 32% on positive late-stage trial results for glaucoma eye drops
finance.yahoo.com - May 24 at 8:23 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Aerie Pharmaceuticals Inc (AERI) a $56.00 Price Target
www.americanbankingnews.com - May 23 at 9:58 PM
finance.yahoo.com logoImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher
finance.yahoo.com - May 19 at 9:43 AM
finance.yahoo.com logoGlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7%
finance.yahoo.com - May 19 at 9:43 AM
seekingalpha.com logoKeeping A Bullish Eye On Aerie Pharmaceuticals - Seeking Alpha
seekingalpha.com - May 17 at 3:23 PM
nasdaq.com logoAerie's (AERI) Rhopressa NDA Sufficient for FDA Review
www.nasdaq.com - May 16 at 8:24 PM
finance.yahoo.com logoAerie's (AERI) Rhopressa NDA Sufficient for FDA Review
finance.yahoo.com - May 16 at 8:24 PM
businesswire.com logoAerie Pharmaceuticals Announces New Hires - Business Wire (press release)
www.businesswire.com - May 16 at 3:23 PM
businesswire.com logoAerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa™ (netarsudil ophthalmic ... - Business Wire (press release)
www.businesswire.com - May 16 at 6:16 AM

Social

Chart

Aerie Pharmaceuticals (AERI) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff